We report a case of autologous hematopoietic recovery with durable leukemic remission after BMT from a phenotypically HLA-identical donor in a 30-year-old male with CML. Graft loss was diagnosed from day 60 post-BMT by VNTR PCR. To assess for the presence of a minor donor-derived T cell population that could exert an anti-leukemic effect, we serially applied a sensitive process of chimerism analysis by fluorescent PCR on sorted T cells. No residual donor T cells could be detected. We also showed retrospectively that a very sensitive method of MRD analysis by real-time quantitative PCR could have permitted prediction of relapse in this case. Bone Marrow Transplantation (2001) 28, 717-720.
have described cases of patients with autologous and nonmalignant hematopoietic reconstitution following allogeneic BMT. This uncommon complication has been exclusively reported in cases of CML, most often when patients were grafted in the chronic phase of the disease. After a prolonged duration of disease remission, the majority of patients relapsed, but a few of them remained disease-free long-term. 7 Clinical factors, as well as mechanisms inducing autologous reconstitution without disease relapse in these patients, are still unknown. The presence of a minor donor-derived lymphoid cell population exerting an anti-leukemic effect might explain the prolonged remissions observed in some patients. To test this hypothesis, we applied a sensitive process of chimerism analysis specifically to T cells, in a case of autologous reconstitution combined with durable molecular remission, after allogeneic BMT for CML.
Case report
A 30-year-old male was diagnosed with CML in chronic phase with the Ph chromosome and no additional chromosomal abnormality in May 1995. He received interferon-␣ (IFN-␣) and hydroxyurea for 6 months, but IFN-␣ had to be interrupted because of a depressive syndrome. He underwent allogeneic BMT from a phenotypically HLAidentical male unrelated donor in March 1996. At that time, he was still in the first chronic phase of the disease. He was conditioned with cyclophosphamide 60 mg/kg per day on days Ϫ5 and Ϫ4, and a 12 Gy TBI on day Ϫ1. He received an unmanipulated graft of 3.2 ϫ 10 8 nucleated cells/kg. GVHD prophylaxis consisted of short-term MTX (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6) and CsA from day Ϫ1. On day 9, he developed acute cutaneous and digestive GVHD, which was documented by colonic biopsies. He was treated with methylprednisolone (maximum dose: 2 mg/kg/day for 2 days), with a complete clinical response. The WBC count reached 1 ϫ 10 3 /l on day 20, but returned to a low level on day 25. Bone marrow was hypoplastic and no viral or toxic cause of cytopenia was found. He received G-CSF from day 33 and the WBC count recovered definitively (Ͼ1 ϫ 10 3 /l) on day 45.
Chimerism analysis
In a first step, chimerism was analyzed from blood and bone marrow cells using standard PCR amplification of a variable number of tandem repeat (VNTR) sequences, analyzed in ethidium bromide-stained gels. Two VNTR markers (D1S80 and ApoB) were found to be informative for this patient, and therefore amplified using the conditions previously described. 8 On day 26, just before receiving G-CSF, PBMC and blood PMN, as well as marrow cells, were of mixed origin, with a large predominance of donor cells (not shown). Nevertheless, from day 60, donor cells were no longer detected. In order to detect a minority population of donor cells, we sought to increase the sensitivity of the process by using fluorescent primers and automated GeneScan analysis of PCR products. With this method, the sensitivity of detection of the donor allele in a background of recipient DNA was 1% with the two VNTR markers, which represented a two-to 10-fold increase of sensitivity against
Bone Marrow Transplantation the detection in ethidium bromide-stained gel. 9 Chimerism analyses were serially performed with this method on PBMC, but also on sorted T cells and on cultured hematopoietic progenitors, at six time points between 4 and 20 months post transplant. T cells were sorted using anti-CD3 mouse antibodies and magnetic DynaBeads coupled with a rat anti-mouse Ig (Dynal RAM IgG1 CELLection kit; Dynal, Oslo, Norway). The purity of T cell samples included for PCR analysis was more than 90%. Hematopoietic progenitors were cultured in methylcellulose for 14 days. Five to 10 colonies of CFU-GM and BFU-E were taken, rinsed with PBS, and mixed for PCR analysis. For T cells and colony samples, PCR amplification was performed directly on cell lysate (0.45% Tween and 400 mg/l proteinase K). For unsorted PBMC samples, PCR amplification was performed after DNA extraction, using 100 ng of spectrophotometrically quantitated DNA. Figure 1 shows the results of analyses obtained at 17 months post BMT for PBMC, T cells, and CFU-GM and BFU-E colonies. At that time, as well as in serial analyses performed between months 4 and 20, all cells were of recipient origin, without any detection of donor cells. 
Molecular and cytogenetic analysis of minimal residual disease
Karyotype and bcr-abl mRNA analyses by one-step RT-PCR (sensitivity ϭ 10
Ϫ3
-10
Ϫ4
) were serially performed on blood cells after transplant. The first molecular analysis was performed 6 months after BMT and indicated that the patient was in molecular remission despite autologous reconstitution. At the same time, no Ph ϩ cells were found in cytogenetic analysis, but a large number of other chromosomal aberrations were present. Among 21 metaphases analyzed, seven were normal: 46,XY; and 14 had several abnormalities: 43-46, XY, del(1q34) [3] , del(2q23) [2] , del(6p22) [2] , del(7q32) [3] ,del(7q31) [4] , Ϫ18 [2] . In eight serial analyses, no evidence of residual disease could be detected either by molecular or by cytogenetic studies until the 37th month post BMT. At that time, the reappearance of malignant cells was revealed by RT-PCR, and was followed by reappearance of Ph ϩ cells 9 months later. IFN-␣ was reintroduced in month 52, at low doses because the patient had previously developed a depressive syndrome under this treatment. As of May 2001, the patient has achi-eved a complete cytogenetic response. Depression did not reappear under IFN-␣.
Retrospectively, we analyzed the evolution of minimal residual disease in this case report, using a new real-time quantitative RT-PCR 10 on cryopreserved cell samples. The early stage post transplant could not be investigated because of lack of preserved samples until the 14th month post transplant. With this more sensitive method (10
Ϫ5
-10 Ϫ6 ), we found that this patient probably never achieved complete molecular remission after BMT. The ratio of copy number of bcr-abl mRNA to a reference sequence (housekeeping gene pbgd mRNA) was minimal at 14 months post BMT (0.003%), and progressively increased further, with a maximum of 24% bcr-abl mRNA/pbgd mRNA by month 52 (Figure 2 ). After reintroduction of IFN-␣ in month 52, a progressive but incomplete disappearance of the bcr-abl transcript could be observed, reaching 1% bcr-abl mRNA/pbgd mRNA at the last determination, after 19 months of IFN-␣.
Discussion
Graft failure followed by autologous and non-malignant hematopoietic recovery is an uncommon complication after allogeneic BMT. More frequently, graft loss results either in prolonged aplasia or leukemic relapse. Although T cell depletion and less intense conditioning are known to predispose to graft failure, clinical factors that lead to autologous reconstitution are not well defined. A recent study has raised the fact that all cases already published concerned patients with CML. 7 It was also suggested that this complication could occur more frequently after unrelated donor BMT, as was the case in the present report.
We sought to further study mechanisms that lead to autologous reconstitution without relapse. In particular, we wanted to assess the presence of a minor donor-derived lymphoid cell population that could exert a GVL effect Bone Marrow Transplantation against CML cells. To answer this question, the sensitivity of the process used for chimerism analysis was the essential parameter to be considered. A minority population of donor cells could be undetected against a background of recipient cells if an insensitive process were used. Thus, we employed an automated detection of fluorescent VNTR-PCR products, which provided a two-to 10-fold increase of sensitivity against the detection in ethidium bromidestained gel. The application of this process to the sorted T cells provided an additional increase of sensitivity for the detection of residual donor T cells.
In the early period post transplant, although no lineagespecific chimerism analysis could be performed, the presence of donor T cells was strongly suggested by mixed chimerism found in PBMC. This presence was also supported by the occurrence of documented GVHD, on day 9 post BMT. In contrast, from the 4th month after transplant, we could not detect residual donor cells among PBMC or T cells, at a level of sensitivity of 1%. Although the presence of donor T cells could not be excluded under this level of sensitivity, we hypothesize that donor T cells were only present at a significant level in the first months following BMT. They may have been responsible for the prolonged clinical remission by exerting a transient GVL effect against CML cells. On the other hand, prolonged eradication of leukemic cells observed in our case may also reflect the efficacy of the conditioning regimen. Indeed, the role of conditioning in the maintenance of autologous remissions has been previously suggested by cases of prolonged remissions observed after T cell-depleted transplant, ie when no extensive T cell-mediated GVL effect can occur. 1, 4, 5 A T cell-specific chimerism analysis has been reported in only one previous case of autologous and non-malignant hematopoietic reconstitution after transplant. 6 Using FISH analysis of the Y chromosome, Wakui et al 6 documented, more than 1 year after grafting, complete recovery of hostderived hematopoiesis in the bone marrow, but mixed T cell chimerism in the peripheral blood. This long-lasting persistence of donor T cells was associated with a prolonged disease remission, of at least 2 years post transplant.
Retrospectively, we also demonstrated that when our patient was thought to be in molecular remission using single-step PCR, a more sensitive and real-time PCR could detect residual leukemic cells. This information would have helped to predict relapse occurrence earlier in this case. Therefore, such a sensitive and quantitative method of minimal residual disease analysis could be of help in patients with autologous hematopoietic recovery to distinguish those who are going to relapse from those who may remain disease-free in the long term.
